Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) reported Q1 EPS of ($2.23), $2.12 worse than the analyst estimate of ($0.11).

For earnings history and earnings-related data on Salarius Pharmaceuticals, Inc. (SLRX) click here.